The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Companion Diagnostics for Oncology Market Research Report 2025
Synopsis
Companion diagnostic (CDx) is a diagnostic testing kit majorly used by pharmaceutical companies for the development of personalized medicine. CDx tests provide information about the effective use of a corresponding therapeutic product by analyzing the genetic material. With the rise in cancer prevalence, coupled with increasing strategic initiatives, there has been a huge demand for companion diagnostics in the oncology area.
The global Companion Diagnostics for Oncology market was valued at US$ 4101 million in 2023 and is anticipated to reach US$ 8392.9 million by 2030, witnessing a CAGR of 10.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Companion Diagnostics for Oncology, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Companion Diagnostics for Oncology.
Report Scope
The Companion Diagnostics for Oncology market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Companion Diagnostics for Oncology market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Companion Diagnostics for Oncology companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Agilent Technologies
Illumina
Roche
BioMérieux
Foundation Medicine
ArcherDX
Qiagen
Thermo Fisher Scientific
Amoy Diagnostics
Abbott
Segment by Type
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Segment by Application
Pharmaceutical and Biopharmaceutical Companies
Contract Research Organizations
Laboratories
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Companion Diagnostics for Oncology companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Companion diagnostic (CDx) is a diagnostic testing kit majorly used by pharmaceutical companies for the development of personalized medicine. CDx tests provide information about the effective use of a corresponding therapeutic product by analyzing the genetic material. With the rise in cancer prevalence, coupled with increasing strategic initiatives, there has been a huge demand for companion diagnostics in the oncology area.
The global Companion Diagnostics for Oncology market was valued at US$ 4101 million in 2023 and is anticipated to reach US$ 8392.9 million by 2030, witnessing a CAGR of 10.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Companion Diagnostics for Oncology, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Companion Diagnostics for Oncology.
Report Scope
The Companion Diagnostics for Oncology market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Companion Diagnostics for Oncology market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Companion Diagnostics for Oncology companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Agilent Technologies
Illumina
Roche
BioMérieux
Foundation Medicine
ArcherDX
Qiagen
Thermo Fisher Scientific
Amoy Diagnostics
Abbott
Segment by Type
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Segment by Application
Pharmaceutical and Biopharmaceutical Companies
Contract Research Organizations
Laboratories
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Companion Diagnostics for Oncology companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Companion Diagnostics for Oncology Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Polymerase Chain Reaction (PCR)
1.2.3 Next-Generation Sequencing (NGS)
1.3 Market by Application
1.3.1 Global Companion Diagnostics for Oncology Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pharmaceutical and Biopharmaceutical Companies
1.3.3 Contract Research Organizations
1.3.4 Laboratories
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Companion Diagnostics for Oncology Market Perspective (2019-2030)
2.2 Companion Diagnostics for Oncology Growth Trends by Region
2.2.1 Global Companion Diagnostics for Oncology Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Companion Diagnostics for Oncology Historic Market Size by Region (2019-2024)
2.2.3 Companion Diagnostics for Oncology Forecasted Market Size by Region (2025-2030)
2.3 Companion Diagnostics for Oncology Market Dynamics
2.3.1 Companion Diagnostics for Oncology Industry Trends
2.3.2 Companion Diagnostics for Oncology Market Drivers
2.3.3 Companion Diagnostics for Oncology Market Challenges
2.3.4 Companion Diagnostics for Oncology Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Companion Diagnostics for Oncology Players by Revenue
3.1.1 Global Top Companion Diagnostics for Oncology Players by Revenue (2019-2024)
3.1.2 Global Companion Diagnostics for Oncology Revenue Market Share by Players (2019-2024)
3.2 Global Companion Diagnostics for Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Companion Diagnostics for Oncology Revenue
3.4 Global Companion Diagnostics for Oncology Market Concentration Ratio
3.4.1 Global Companion Diagnostics for Oncology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Companion Diagnostics for Oncology Revenue in 2023
3.5 Companion Diagnostics for Oncology Key Players Head office and Area Served
3.6 Key Players Companion Diagnostics for Oncology Product Solution and Service
3.7 Date of Enter into Companion Diagnostics for Oncology Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Companion Diagnostics for Oncology Breakdown Data by Type
4.1 Global Companion Diagnostics for Oncology Historic Market Size by Type (2019-2024)
4.2 Global Companion Diagnostics for Oncology Forecasted Market Size by Type (2025-2030)
5 Companion Diagnostics for Oncology Breakdown Data by Application
5.1 Global Companion Diagnostics for Oncology Historic Market Size by Application (2019-2024)
5.2 Global Companion Diagnostics for Oncology Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Companion Diagnostics for Oncology Market Size (2019-2030)
6.2 North America Companion Diagnostics for Oncology Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Companion Diagnostics for Oncology Market Size by Country (2019-2024)
6.4 North America Companion Diagnostics for Oncology Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Companion Diagnostics for Oncology Market Size (2019-2030)
7.2 Europe Companion Diagnostics for Oncology Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Companion Diagnostics for Oncology Market Size by Country (2019-2024)
7.4 Europe Companion Diagnostics for Oncology Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Companion Diagnostics for Oncology Market Size (2019-2030)
8.2 Asia-Pacific Companion Diagnostics for Oncology Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Companion Diagnostics for Oncology Market Size by Region (2019-2024)
8.4 Asia-Pacific Companion Diagnostics for Oncology Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Companion Diagnostics for Oncology Market Size (2019-2030)
9.2 Latin America Companion Diagnostics for Oncology Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Companion Diagnostics for Oncology Market Size by Country (2019-2024)
9.4 Latin America Companion Diagnostics for Oncology Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Companion Diagnostics for Oncology Market Size (2019-2030)
10.2 Middle East & Africa Companion Diagnostics for Oncology Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Companion Diagnostics for Oncology Market Size by Country (2019-2024)
10.4 Middle East & Africa Companion Diagnostics for Oncology Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Agilent Technologies
11.1.1 Agilent Technologies Company Detail
11.1.2 Agilent Technologies Business Overview
11.1.3 Agilent Technologies Companion Diagnostics for Oncology Introduction
11.1.4 Agilent Technologies Revenue in Companion Diagnostics for Oncology Business (2019-2024)
11.1.5 Agilent Technologies Recent Development
11.2 Illumina
11.2.1 Illumina Company Detail
11.2.2 Illumina Business Overview
11.2.3 Illumina Companion Diagnostics for Oncology Introduction
11.2.4 Illumina Revenue in Companion Diagnostics for Oncology Business (2019-2024)
11.2.5 Illumina Recent Development
11.3 Roche
11.3.1 Roche Company Detail
11.3.2 Roche Business Overview
11.3.3 Roche Companion Diagnostics for Oncology Introduction
11.3.4 Roche Revenue in Companion Diagnostics for Oncology Business (2019-2024)
11.3.5 Roche Recent Development
11.4 BioMérieux
11.4.1 BioMérieux Company Detail
11.4.2 BioMérieux Business Overview
11.4.3 BioMérieux Companion Diagnostics for Oncology Introduction
11.4.4 BioMérieux Revenue in Companion Diagnostics for Oncology Business (2019-2024)
11.4.5 BioMérieux Recent Development
11.5 Foundation Medicine
11.5.1 Foundation Medicine Company Detail
11.5.2 Foundation Medicine Business Overview
11.5.3 Foundation Medicine Companion Diagnostics for Oncology Introduction
11.5.4 Foundation Medicine Revenue in Companion Diagnostics for Oncology Business (2019-2024)
11.5.5 Foundation Medicine Recent Development
11.6 ArcherDX
11.6.1 ArcherDX Company Detail
11.6.2 ArcherDX Business Overview
11.6.3 ArcherDX Companion Diagnostics for Oncology Introduction
11.6.4 ArcherDX Revenue in Companion Diagnostics for Oncology Business (2019-2024)
11.6.5 ArcherDX Recent Development
11.7 Qiagen
11.7.1 Qiagen Company Detail
11.7.2 Qiagen Business Overview
11.7.3 Qiagen Companion Diagnostics for Oncology Introduction
11.7.4 Qiagen Revenue in Companion Diagnostics for Oncology Business (2019-2024)
11.7.5 Qiagen Recent Development
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Detail
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Companion Diagnostics for Oncology Introduction
11.8.4 Thermo Fisher Scientific Revenue in Companion Diagnostics for Oncology Business (2019-2024)
11.8.5 Thermo Fisher Scientific Recent Development
11.9 Amoy Diagnostics
11.9.1 Amoy Diagnostics Company Detail
11.9.2 Amoy Diagnostics Business Overview
11.9.3 Amoy Diagnostics Companion Diagnostics for Oncology Introduction
11.9.4 Amoy Diagnostics Revenue in Companion Diagnostics for Oncology Business (2019-2024)
11.9.5 Amoy Diagnostics Recent Development
11.10 Abbott
11.10.1 Abbott Company Detail
11.10.2 Abbott Business Overview
11.10.3 Abbott Companion Diagnostics for Oncology Introduction
11.10.4 Abbott Revenue in Companion Diagnostics for Oncology Business (2019-2024)
11.10.5 Abbott Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Companion Diagnostics for Oncology Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Polymerase Chain Reaction (PCR)
Table 3. Key Players of Next-Generation Sequencing (NGS)
Table 4. Global Companion Diagnostics for Oncology Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Companion Diagnostics for Oncology Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Companion Diagnostics for Oncology Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Companion Diagnostics for Oncology Market Share by Region (2019-2024)
Table 8. Global Companion Diagnostics for Oncology Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Companion Diagnostics for Oncology Market Share by Region (2025-2030)
Table 10. Companion Diagnostics for Oncology Market Trends
Table 11. Companion Diagnostics for Oncology Market Drivers
Table 12. Companion Diagnostics for Oncology Market Challenges
Table 13. Companion Diagnostics for Oncology Market Restraints
Table 14. Global Companion Diagnostics for Oncology Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Companion Diagnostics for Oncology Market Share by Players (2019-2024)
Table 16. Global Top Companion Diagnostics for Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Companion Diagnostics for Oncology as of 2023)
Table 17. Ranking of Global Top Companion Diagnostics for Oncology Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Companion Diagnostics for Oncology Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Companion Diagnostics for Oncology Product Solution and Service
Table 21. Date of Enter into Companion Diagnostics for Oncology Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Companion Diagnostics for Oncology Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Companion Diagnostics for Oncology Revenue Market Share by Type (2019-2024)
Table 25. Global Companion Diagnostics for Oncology Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Companion Diagnostics for Oncology Revenue Market Share by Type (2025-2030)
Table 27. Global Companion Diagnostics for Oncology Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Companion Diagnostics for Oncology Revenue Market Share by Application (2019-2024)
Table 29. Global Companion Diagnostics for Oncology Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Companion Diagnostics for Oncology Revenue Market Share by Application (2025-2030)
Table 31. North America Companion Diagnostics for Oncology Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Companion Diagnostics for Oncology Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Companion Diagnostics for Oncology Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Companion Diagnostics for Oncology Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Companion Diagnostics for Oncology Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Companion Diagnostics for Oncology Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Companion Diagnostics for Oncology Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Companion Diagnostics for Oncology Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Companion Diagnostics for Oncology Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Companion Diagnostics for Oncology Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Companion Diagnostics for Oncology Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Companion Diagnostics for Oncology Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Companion Diagnostics for Oncology Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Companion Diagnostics for Oncology Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Companion Diagnostics for Oncology Market Size by Country (2025-2030) & (US$ Million)
Table 46. Agilent Technologies Company Detail
Table 47. Agilent Technologies Business Overview
Table 48. Agilent Technologies Companion Diagnostics for Oncology Product
Table 49. Agilent Technologies Revenue in Companion Diagnostics for Oncology Business (2019-2024) & (US$ Million)
Table 50. Agilent Technologies Recent Development
Table 51. Illumina Company Detail
Table 52. Illumina Business Overview
Table 53. Illumina Companion Diagnostics for Oncology Product
Table 54. Illumina Revenue in Companion Diagnostics for Oncology Business (2019-2024) & (US$ Million)
Table 55. Illumina Recent Development
Table 56. Roche Company Detail
Table 57. Roche Business Overview
Table 58. Roche Companion Diagnostics for Oncology Product
Table 59. Roche Revenue in Companion Diagnostics for Oncology Business (2019-2024) & (US$ Million)
Table 60. Roche Recent Development
Table 61. BioMérieux Company Detail
Table 62. BioMérieux Business Overview
Table 63. BioMérieux Companion Diagnostics for Oncology Product
Table 64. BioMérieux Revenue in Companion Diagnostics for Oncology Business (2019-2024) & (US$ Million)
Table 65. BioMérieux Recent Development
Table 66. Foundation Medicine Company Detail
Table 67. Foundation Medicine Business Overview
Table 68. Foundation Medicine Companion Diagnostics for Oncology Product
Table 69. Foundation Medicine Revenue in Companion Diagnostics for Oncology Business (2019-2024) & (US$ Million)
Table 70. Foundation Medicine Recent Development
Table 71. ArcherDX Company Detail
Table 72. ArcherDX Business Overview
Table 73. ArcherDX Companion Diagnostics for Oncology Product
Table 74. ArcherDX Revenue in Companion Diagnostics for Oncology Business (2019-2024) & (US$ Million)
Table 75. ArcherDX Recent Development
Table 76. Qiagen Company Detail
Table 77. Qiagen Business Overview
Table 78. Qiagen Companion Diagnostics for Oncology Product
Table 79. Qiagen Revenue in Companion Diagnostics for Oncology Business (2019-2024) & (US$ Million)
Table 80. Qiagen Recent Development
Table 81. Thermo Fisher Scientific Company Detail
Table 82. Thermo Fisher Scientific Business Overview
Table 83. Thermo Fisher Scientific Companion Diagnostics for Oncology Product
Table 84. Thermo Fisher Scientific Revenue in Companion Diagnostics for Oncology Business (2019-2024) & (US$ Million)
Table 85. Thermo Fisher Scientific Recent Development
Table 86. Amoy Diagnostics Company Detail
Table 87. Amoy Diagnostics Business Overview
Table 88. Amoy Diagnostics Companion Diagnostics for Oncology Product
Table 89. Amoy Diagnostics Revenue in Companion Diagnostics for Oncology Business (2019-2024) & (US$ Million)
Table 90. Amoy Diagnostics Recent Development
Table 91. Abbott Company Detail
Table 92. Abbott Business Overview
Table 93. Abbott Companion Diagnostics for Oncology Product
Table 94. Abbott Revenue in Companion Diagnostics for Oncology Business (2019-2024) & (US$ Million)
Table 95. Abbott Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Companion Diagnostics for Oncology Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Companion Diagnostics for Oncology Market Share by Type: 2023 VS 2030
Figure 3. Polymerase Chain Reaction (PCR) Features
Figure 4. Next-Generation Sequencing (NGS) Features
Figure 5. Global Companion Diagnostics for Oncology Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Companion Diagnostics for Oncology Market Share by Application: 2023 VS 2030
Figure 7. Pharmaceutical and Biopharmaceutical Companies Case Studies
Figure 8. Contract Research Organizations Case Studies
Figure 9. Laboratories Case Studies
Figure 10. Others Case Studies
Figure 11. Companion Diagnostics for Oncology Report Years Considered
Figure 12. Global Companion Diagnostics for Oncology Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Companion Diagnostics for Oncology Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Companion Diagnostics for Oncology Market Share by Region: 2023 VS 2030
Figure 15. Global Companion Diagnostics for Oncology Market Share by Players in 2023
Figure 16. Global Top Companion Diagnostics for Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Companion Diagnostics for Oncology as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Companion Diagnostics for Oncology Revenue in 2023
Figure 18. North America Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Companion Diagnostics for Oncology Market Share by Country (2019-2030)
Figure 20. United States Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Companion Diagnostics for Oncology Market Share by Country (2019-2030)
Figure 24. Germany Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Companion Diagnostics for Oncology Market Share by Region (2019-2030)
Figure 32. China Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Companion Diagnostics for Oncology Market Share by Country (2019-2030)
Figure 40. Mexico Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Companion Diagnostics for Oncology Market Share by Country (2019-2030)
Figure 44. Turkey Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Companion Diagnostics for Oncology Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Agilent Technologies Revenue Growth Rate in Companion Diagnostics for Oncology Business (2019-2024)
Figure 47. Illumina Revenue Growth Rate in Companion Diagnostics for Oncology Business (2019-2024)
Figure 48. Roche Revenue Growth Rate in Companion Diagnostics for Oncology Business (2019-2024)
Figure 49. BioMérieux Revenue Growth Rate in Companion Diagnostics for Oncology Business (2019-2024)
Figure 50. Foundation Medicine Revenue Growth Rate in Companion Diagnostics for Oncology Business (2019-2024)
Figure 51. ArcherDX Revenue Growth Rate in Companion Diagnostics for Oncology Business (2019-2024)
Figure 52. Qiagen Revenue Growth Rate in Companion Diagnostics for Oncology Business (2019-2024)
Figure 53. Thermo Fisher Scientific Revenue Growth Rate in Companion Diagnostics for Oncology Business (2019-2024)
Figure 54. Amoy Diagnostics Revenue Growth Rate in Companion Diagnostics for Oncology Business (2019-2024)
Figure 55. Abbott Revenue Growth Rate in Companion Diagnostics for Oncology Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
